Tocilizumab Other names: Atlizumab

Therapeutic indications

Tocilizumab is indicated for:

Rheumatoid arthritis (RA)

Population group: only adults (18 years old or older)

Tocilizumab, in combination with methotrexate, is indicated for:

  • the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate.
  • the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.

In these patients, tocilizumab can be given as monotherapy in case of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate. Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Systemic juvenile idiopathic arthritis (sJIA)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Tocilizumab is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. Tocilizumab can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Juvenile idiopathic polyarthritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Tocilizumab in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cytokine Release Syndrome (CRS)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Tocilizumab is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tocilizumab is contraindicated in the following cases:

Active, severe infections

Infectious disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: RoACTEMRA Concentrate for solution for infusion
Structured Product Labeling (SPL/PLR) 2020: ACTEMRA Solution for injection
Summary of Product Characteristics (SPC) 2019: RoACTEMRA Solution for injection in pre-filled syringe
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈